09:42 AM EDT, 10/28/2026 (MT Newswires) -- SNB Capital Research took note of Nahdi Medical's (SASE:4164) "in-line set" of earnings in the third quarter in an analysis published Wednesday. Thanks to "strong" performances across its business units, the retail pharmacy and healthcare company logged a 9.4% annual growth in revenue to 2.69 billion Saudi riyals, which slightly surpassed SNB Capital's forecast of 2.60 billion riyals. Net income, meanwhile, rose 6.5% year over year to 172 million riyals, compared with the 174 million-riyal estimate of the research firm. "Based on our last update, we are Overweight on Nahdi with a PT of SAR109.5. Continued topline growth remains the key positive, while we believe margin contraction and persistent pressure from opex investments are a near-term concern. However, we view these investments as supportive of LT growth, as it would move Nahdi away from its previous business structure that relied solely on retail, which carries higher margins but faces higher competition. We view Nahdi's diversification as favourable," analysts wrote.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.